Zobrazeno 1 - 10
of 69
pro vyhledávání: '"Amit S. Kulkarni"'
Publikováno v:
Viruses, Vol 6, Iss 3, Pp 968-985 (2014)
Human cytomegalovirus (HCMV) is a ubiquitous pathogen capable of causing life threatening consequences in neonates and immune-compromised individuals. HCMV inflicts site-specific double strand breaks (DSBs) in the cellular genome. DNA damage inflicti
Externí odkaz:
https://doaj.org/article/3f90c692b959407cb1efd5ef7e236203
Autor:
Jean-Philippe Metges, Mayur Amonkar, Christelle De La Fouchardiere, Amit S. Kulkarni, Wasat Mansoor, Antoine Adenis, Raed Al-Rajabi, Pooja Bhagia, Hanneke W. M. van Laarhoven, Shailaja Suryawanshi, Josephine M. Norquist, Gustavo Girotto, Hélène Senellart
Publikováno v:
Journal of clinical oncology, 40(4), 382-391. American Society of Clinical Oncology
Adenis, A, Kulkarni, A S, Girotto, G C, de la Fouchardiere, C, Senellart, H, van Laarhoven, H W M, Mansoor, W, Al-Rajabi, R, Norquist, J, Amonkar, M, Suryawanshi, S, Bhagia, P & Metges, J-P 2022, ' Impact of Pembrolizumab Versus Chemotherapy as Second-Line Therapy for Advanced Esophageal Cancer on Health-Related Quality of Life in KEYNOTE-181 ', Journal of clinical oncology : official journal of the American Society of Clinical Oncology, vol. 40, no. 4, pp. 382-391 . https://doi.org/10.1200/JCO.21.00601
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 40(4), 382-391. American Society of Clinical Oncology
Adenis, A, Kulkarni, A S, Girotto, G C, de la Fouchardiere, C, Senellart, H, van Laarhoven, H W M, Mansoor, W, Al-Rajabi, R, Norquist, J, Amonkar, M, Suryawanshi, S, Bhagia, P & Metges, J-P 2022, ' Impact of Pembrolizumab Versus Chemotherapy as Second-Line Therapy for Advanced Esophageal Cancer on Health-Related Quality of Life in KEYNOTE-181 ', Journal of clinical oncology : official journal of the American Society of Clinical Oncology, vol. 40, no. 4, pp. 382-391 . https://doi.org/10.1200/JCO.21.00601
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 40(4), 382-391. American Society of Clinical Oncology
PURPOSE In the phase III KEYNOTE-181 study ( NCT02564263 ) of patients with advanced esophageal cancer (EC), pembrolizumab monotherapy prolonged overall survival versus chemotherapy as second-line therapy in patients with programmed death ligand 1 co
Autor:
Baek-Yeol Ryoo, Ho Yeong Lim, Marcelo Garrido, Sadahisa Ogasawara, Yee Chao, Erluo Chen, Ann-Lii Cheng, Josephine M. Norquist, Thomas Yau, Bruno Daniele, Masatoshi Kudo, Valeriy Breder, Richard S. Finn, Stephen L. Chan, Philippe Merle, Julien Edeline, Andrew X. Zhu, Amit S. Kulkarni, Abby B. Siegel, Mohamed Bouattour
Publikováno v:
Cancer. 127:865-874
Background Health-related quality of life (HRQoL) is an important outcome measure and prognostic indicator in hepatocellular carcinoma (HCC). KEYNOTE-240 (NCT02702401) assessed the efficacy and safety of pembrolizumab plus best supportive care (BSC)
Autor:
Apichai Vasuratna, Amit S. Kulkarni, Piyalamporn Havanond, Andrew Pavelyev, Nipon Khemapech, Preyanuch Deebukkham, Wichai Termrungruanglert
Publikováno v:
PLoS ONE, Vol 16, Iss 2, p e0245894 (2021)
PLoS ONE
PLoS ONE
Background The human papillomavirus (HPV) vaccine was introduced into Thailand’s national immunization program in 2017 for 11–12 year old school girls. The objectives of this study were to examine the epidemiological consequences and cost-effecti
Autor:
Amit S. Kulkarni, Clemens Bretscher, Tiago Ferreira, Marcelo Ehrlich, Karsten Richter, Antonio Marchini
Publikováno v:
Viruses
Viruses, Vol 12, Iss 1199, p 1199 (2020)
Volume 12
Issue 10
Viruses, Vol 12, Iss 1199, p 1199 (2020)
Volume 12
Issue 10
H-1 protoparvovirus (H-1PV) is a self-propagating virus that is non-pathogenic in humans and has oncolytic and oncosuppressive activities. H-1PV is the first member of the Parvoviridae family to undergo clinical testing as an anticancer agent. Result
Publikováno v:
BJOG: An International Journal of Obstetrics & Gynaecology. 125:478-486
Objective To examine the epidemiological and economic impact of a nine-valent (nonavalent) human papillomavirus (HPV) 6/11/16/18/31/33/45/52/58 vaccine programme for young teenagers in Singapore. Design Mathematical modelling. Setting Pharmaco-econom
Publikováno v:
International Journal of Gynecology & Obstetrics. 137:129-137
Objective To investigate the clinical and economic impacts of school-based administration of the quadrivalent HPV vaccine. Methods A retrospective health-economic analysis was conducted using data collected in Singapore between 2004 and 2005. A dynam
Autor:
Jean-Philippe Metges, Zhigang Li, Toshihiko Doi, Ken Kato, Peter C. Enzinger, Jong-Mu Sun, Antoine Adenis, Sung-Bae Kim, Lin Shen, Takashi Kojima, Byoung Chul Cho, Eray Goekkurt, Sukrut Shah, Patrapim Sunpaweravong, Amit S. Kulkarni, Josephine M. Norquist, Manish A. Shah, Shailaja Suryawanshi, Maria Alsina, Wasat Mansoor
Publikováno v:
Journal of Clinical Oncology. 39:168-168
168 Background: In the randomized, international, double-blind, placebo-controlled KEYNOTE-590 (NCT03189719) study, pembrolizumab (pembro) + chemotherapy (chemo) provided statistically significant and clinically meaningful improvement in OS, PFS, and
Publikováno v:
Journal of Virological Methods. 198:64-68
This report describes the development of a novel dual color Southern protocol to visualize two distinct genomes or genic regions simultaneously on a single Southern blot. The blot is developed with IRDye-conjugated antibody (Ab) and streptavidin that
Autor:
A-L Cheng, Marcelo Garrido, Amit S. Kulkarni, Masatoshi Kudo, Erluo Chen, Thomas Yau, Josephine M. Norquist, Richard S. Finn, Valeriy Breder, Sheng-Ju Chan, Yee Chao, Baek-Yeol Ryoo, Andrew X. Zhu, Sadahisa Ogasawara, H. Y. Lim, Bruno Daniele, Philippe Merle, Julien Edeline, Abby B. Siegel, Mohamed Bouattour
Publikováno v:
Annals of Oncology. 30:v256
Background KEYNOTE-240 (ClinicalTrials.gov: NCT02702401) is a double-blind, randomized, placebo-controlled, phase 3 trial that evaluated pembro 200 mg every 3 weeks compared with BSC in pts with advanced HCC who were previously systemically treated.